Literature DB >> 16702730

Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population.

Keiko Maekawa1, Masaya Itoda, Kimie Sai, Yoshiro Saito, Nahoko Kaniwa, Kuniaki Shirao, Tetsuya Hamaguchi, Hideo Kunitoh, Noboru Yamamoto, Tomohide Tamura, Hironobu Minami, Kaoru Kubota, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Naoyuki Kamatani, Shogo Ozawa, Jun-ichi Sawada.   

Abstract

The ATP-binding cassette transporter, ABCG2, which is expressed at high levels in the intestine and liver, functions as an efflux transporter for many drugs, including clinically used anticancer agents such as topotecan and the active metabolite of irinotecan (SN-38). In this study, to elucidate the linkage disequilibrium (LD) profiles and haplotype structures of ABCG2, we have comprehensively searched for genetic variations in the putative promoter region, all the exons, and their flanking introns of ABCG2 from 177 Japanese cancer patients treated with irinotecan. Forty-three genetic variations, including 11 novel ones, were found: 5 in the 5'-flanking region, 13 in the coding exons, and 25 in the introns. In addition to 9 previously reported nonsynonymous single nucleotide polymorphisms (SNPs), 2 novel nonsynonymous SNPs, 38C>T (Ser13Leu) and 1060G>A (Gly354Arg), were found with minor allele frequencies of 0.3%. Based on the LD profiles between the SNPs and the estimated past recombination events, the region analyzed was divided into three blocks (Block -1, 1, and 2), each of which spans at least 0.2 kb, 46 kb, and 13 kb and contains 2, 24, and 17 variations, respectively. The two, eight, and five common haplotypes detected in 10 or more patients accounted for most (>90%) of the haplotypes inferred in Block -1, Block 1, and Block 2, respectively. The SNP and haplotype distributions in Japanese were different from those reported previously in Caucasians. This study provides fundamental information for the pharmacogenetic studies investigating the relationship between the genetic variations in ABCG2 and pharmacokinetic/pharmacodynamic parameters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702730     DOI: 10.2133/dmpk.21.109

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  6 in total

1.  Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma.

Authors:  Renpei Kato; Yoichiro Kato; Tomohiko Matsuura; Mitsugu Kanehira; Ryo Takata; Wataru Obara
Journal:  BMC Cancer       Date:  2017-03-23       Impact factor: 4.430

2.  Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout.

Authors:  Yu Toyoda; Kateřina Pavelcová; Jana Bohatá; Pavel Ješina; Yu Kubota; Hiroshi Suzuki; Tappei Takada; Blanka Stiburkova
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 5.923

3.  Suspected anemia caused by maternal anti-Jra antibodies: a case report.

Authors:  Yasufumi Endo; Shoichi Ito; Yoshiko Ogiyama
Journal:  Biomark Res       Date:  2015-08-21

4.  A comprehensive analysis of the association of common variants of ABCG2 with gout.

Authors:  Kuang-Hui Yu; Pi-Yueh Chang; Shih-Cheng Chang; Yah-Huei Wu-Chou; Li-An Wu; Ding-Pin Chen; Fu-Sung Lo; Jang-Jih Lu
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

5.  Transmembrane Domain Single-Nucleotide Polymorphisms Impair Expression and Transport Activity of ABC Transporter ABCG2.

Authors:  Noora Sjöstedt; Jeroen J M W van den Heuvel; Jan B Koenderink; Heidi Kidron
Journal:  Pharm Res       Date:  2017-03-09       Impact factor: 4.200

6.  Comprehensive Analysis of ABCG2 Genetic Variation in the Polish Population and Its Inter-Population Comparison.

Authors:  Marcin Słomka; Marta Sobalska-Kwapis; Małgorzata Korycka-Machała; Jarosław Dziadek; Grzegorz Bartosz; Dominik Strapagiel
Journal:  Genes (Basel)       Date:  2020-09-29       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.